Affiliation:
1. Warren and Katharine Schlinger Laboratory of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
2. Division of Hematology/Oncology, Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Abstract
Journey to jorumycin
Jorumycin is a structurally complex, pentacyclic organic compound produced by a marine mollusk. The success of a similar compound, trabectedin, in treating certain types of cancer has focused attention on exploring jorumycin's pharmaceutical properties. Welin
et al.
developed a succinct route to synthesizing jorumycin and the closely related jorunnamycin A that deliberately diverges from the putative biosynthetic pathway underlying prior chemical syntheses. This route, which hinges on a carefully optimized asymmetric catalytic hydrogenation, can be easily modified to introduce unnatural structural diversity for functional optimization in further drug discovery research.
Science
, this issue p.
270
Funder
National Science Foundation
American Cancer Society
National Institute of General Medical Sciences
Alexander von Humboldt-Stiftung
California HIV/AIDS Research Program
German Academic Exchange Service
Margaret E. Early Trust
Teva Pharmaceuticals Marc A. Goshko Memorial Grant Program
Royal Thai Government Scholarship program
Austrian Science Fund
Swiss National Science Foundation
Oticon Fonden
Knud Højgaards Fond
Publisher
American Association for the Advancement of Science (AAAS)
Cited by
99 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献